Business Wire - Orexigen® Therapeutics Announces That Contrave® May Reverse the Incidence of Metabolic Syndrome
Thursday, December 4th, 2008 Shows Potential to Reduce Risks for Diabetes and Heart Disease
SAN FRANCISCO & SAN DIEGO — Orexigen([R]) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that based on a review of data from its Contrave([R]) Phase IIb trial, patients assigned to Contrave dosage groups demonstrated a 50% reduction in the prevalence…
